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the strength of the anti-CMV response
in nonagenarians
Saara Marttila1,2*, Juulia Jylhävä1,2, Laura Kananen1,2, Antti Hervonen2,3, Marja Jylhä2,3 and Mikko Hurme1,2,4Abstract
Background: Infection with human cytomegalovirus (CMV) affects the function and composition of the immune
system during ageing. In addition to the presence of the pathogen, the strength of the immune response, as
measured by the anti-CMV IgG titre, has a significant effect on age-related pathogenesis. High anti-CMV IgG titres
have been associated with increased mortality and functional impairment in the elderly. In this study, we were
interested in identifying the molecular mechanisms that are associated with the strength of the anti-CMV response
by examining the gene expression profiles that are associated with the level of the anti-CMV IgG titre.
Results: The level of the anti-CMV IgG titre is associated with the expression level of 663 transcripts in nonagenarians.
These transcripts and their corresponding pathways are, for the most part, associated with metabolic functions, cell
development and proliferation and other basic cellular functions. However, no prominent associations with the
immune system were found, and no associated transcripts were found in young controls.
Conclusions: The lack of defence pathways associated with the strength of the anti-CMV response can indicate that
the compromised immune system can no longer defend itself against the CMV infection. Our data imply that the
association between high anti-CMV IgG titres and increased mortality and frailty is mediated by basic cellular processes.
Keywords: Cytomegalovirus, Anti-CMV IgG titre, Nonagenarians, Elderly, Transcriptomics, Immune response, Pathway
analysis, Upstream regulatorBackground
Cytomegalovirus (CMV), a common herpes virus also
known as HHV5, initially causes an asymptomatic pri-
mary infection and then remains latent in the body,
typically in the myeloid cell compartment. Primary
CMV infection typically occurs in childhood, and the
seroprevalence in the population increases with age,
reaching 85-90% at ages of 75-80 years [1].
Strong evidence suggests that CMV-seropositivity is
associated with dramatic changes in the immune system,
especially in the T cell compartment. In the CD4+ and
CD8+ T-cell populations, the proportion of naïve cells
is decreased, while the proportion of memory cells is
increased in CMV-seropositive individuals [2-5]. However,* Correspondence: saara.marttila@uta.fi
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stated.the specific role of CMV in these ageing-associated
changes remains controversial, although it can be said
that CMV at least accelerates detrimental changes [1].
In a recent transcriptomic analysis, we have shown that
the CMV-associated and CMV-independent ageing effects
on the immune system are different: CMV seropositive no-
nagenarians show alterations in dendritic cell maturation,
B cell development and T helper cell differentiation that
are not present in CMV seronegative nonagenarians [6].
Several epidemiological studies imply that the strength
of the anti-CMV response, quantitated based on the anti-
CMV titre, is of significance in age-related pathogenesis
(reviewed in [1]), and high anti-CMV titres are associated
with all-cause and cardiovascular mortality [7-10]. Our
previous results show that CMV infection and anti-CMV
titre are also associated with impaired vascular function
in males at a young age [11]. A high anti-CMV titre has
also been linked with increased frailty and functional
impairment [12-14], although conflicting reports exist withLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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been shown to correlate with the T cell proportions [16].
Several factors make the analysis of the exact role of
CMV in the pathogenesis of these changes in the human
immune system difficult. As the primary CMV infection
is typically asymptomatic, CMV resides in cells in a latent
form with the potential to reactivate, and reinfection with
a new strain is also possible, a study that includes a long
follow-up period would be required to obtain information
about the effects of reactivation and reinfection on the
level of anti-CMV IgG titres and to further understand the
significance of these processes on the phenotypic changes
that are observed in the elderly. In addition, the direct
measurement of the anti-CMV immune response (i.e., the
T cell response or antibody formation against the various
CMV epitopes) is challenging, and these methods are
rarely available in a long-term follow-up setting.
To obtain detailed information on the molecular mecha-
nisms that are associated with the strength of the anti-
CMV immune response, we performed a genome-wide
transcriptomic analysis of peripheral blood mononuclear
cells (PBMC) from 138 CMV-seropositive nonagenarians
and have correlated the transcript data with anti-CMV
IgG titres.
Results
Our analysis was performed using the 2010 cohort of
the Vitality 90+ study population. This study cohort con-
sists of individuals born in 1920 and living in the city of
Tampere, Finland. Home-dwelling and institutionalised
individuals are included in this study cohort, and all are
of Western European descent. The incidence of CMV
seropositivity was high, as 96% (138 of 144) of individuals
were anti-CMV IgG seropositive. As in previous studies
(see Background), a higher titre was associated with func-
tional impairments in nonagenarians as the anti-CMV
IgG titre was inversely correlated with handgrip strength
(n = 130, Spearman’s rho =−0.233 p = 0.011) and the Barthel
index (n = 138, Spearman’s rho = −0.218, p = 0.010).
To elucidate the molecular mechanisms that are associ-
ated with the strength of the anti-CMV immune response,
as measured by the anti-CMV IgG titre, we performed
a correlation analysis between the level of the anti-
CMV IgG titre and global gene expression levels. In the
correlation analysis, we found 663 transcripts whose
expression level correlated with the level of the anti-CMV
titre (Pearson correlation coefficient, Benjamini-Hochberg
FDR < 0.20). Of the correlating transcripts, the expression
level of 290 transcripts was inversely correlated with
the anti-CMV IgG titre, and the expression level of 373
transcripts was directly correlated. The transcripts with the
highest correlation coefficients were EIF4BP3 (Pearson’s
r = −0.327), LSM4 (r = −0.311), NUAK2 (r = −0.302), TCP1
(r = 0.351), KIAA0947 (r = 0.348) and WAC (r = 0.348). Acomplete list of the correlating transcripts can be found
in Additional file 1: Table S1.
We then performed canonical pathway analysis to
identify the pathways that are affected by the level of the
anti-CMV IgG titre. We identified 26 such pathways, and
they are listed in Additional file 2: Table S2. The most
significant pathways included 3-phosphoinositide biosyn-
thesis, Dolichyl-diphosphooligosaccharide biosynthesis and
3-phosphoinositide degradation. The canonical pathways
were further categorised into pathway categories (Figure 1).
The eight most affected pathways were metabolic path-
ways, and 12 of the 26 affected pathways were metabolic
pathways. The most represented signalling pathway
categories were Cellular growth and Proliferation and
development.
Upstream regulator analysis was also used to identify
molecules that were predicted to be activated or inacti-
vated based on the expression data (Table 1). By definition,
the upstream regulators are molecules that can affect the
expression of other molecules. In nonagenarians, we iden-
tified 4 affected upstream regulators, CD24, Mek, IFNL1
and AR, all of which were predicted to be activated.
We also aimed to repeat the correlation analysis in
young controls (n = 30). The incidence of anti-CMV
seropositivity was lower in the young controls compared
with nonagenarians as 63% (19 of 30) of the controls
were anti-CMV IgG seropositive. Additionally, the median
CMV titre was significantly lower in young controls
compared with nonagenarians (7 200 and 19 500, re-
spectively, Mann–Whitney U-test, p < 0.001). Details
of the anti-CMV IgG titres are presented in Additional
file 3: Table S3. However, we found no transcripts that
were significantly associated with the level of anti-CMV
IgG titre in the young controls (Pearson correlation
coefficient, Benjamini-Hochberg FDR < 0.20).
Discussion
The aim of this analysis was to identify the molecular
mechanisms that are associated with the strength of the
anti-CMV response and to thus shed light on the associ-
ation between high anti-CMV IgG titres and increased
mortality, frailty and functional impairment in the elderly.
We identified 663 transcripts that were associated with
the strength of the anti-CMV response and further
characterised these using pathway analysis tools. The
data indicate that the strength of the anti-CMV response
in nonagenarians has widespread effects on the cells of the
immune system that range from basic cellular processes to
metabolic processes and immune functions.
The majority of the canonical pathways that were
associated with the level of anti-CMV IgG titre were
metabolic pathways, e.g., the cholesterol and inositol
processing pathways. Of the remaining pathways, classified
as signalling pathways, the most represented categories
0 2 4 6 8 10 12
Organismal growth & development
Cell cycle regulation
Apoptosis
Cellular immune response
Humoral immune response
Neurotransmitters & nervous system signalling
Cytokine signalling
Cellular stress & injury
Intracellular & 2nd messenger signalling
Growth factor signalling
Cellular growth
Proliferation & development
Metabolic pathway
Figure 1 Pathway categories that were affected by the level of the anti-CMV IgG titre. The numbers of pathways in the indicated pathway
categories for nonagenarians are listed. Canonical pathways that were affected by the anti-CMV IgG titre are grouped into pathway categories
that are defined in the Ingenuity Knowledge Base®. One canonical pathway can belong to several categories.
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Only two immune system-associated pathways were
represented, and interestingly, none were explicitly associ-
ated with B cell function. Based on the pathway analysis, it
appears that the effects of the strength of the anti-CMV
response are focused on the basic functions of the cell in
nonagenarians.
Additionally, when studying the single transcripts that
were associated with the level of the anti-CMV IgG titre,
it can be observed that the basic functions of the cell are
represented. The top 20 correlated transcripts (directly
and inversely) included several translation and mRNA
processing-related genes, ER-associated genes and different
signalling molecules. When studying the groups of directly
and inversely correlated transcripts, transcripts associated
with metabolic processes, signal transduction, gene expres-
sion and RNA processing, as well as cell death, could be
found in both groups. For a list of all transcripts that were
associated with the anti-CMV-IgG titre, see Additional
file 1: Table S1.
However, when studying single transcripts or canonical
pathways, the direction of change in the different cellular
processes cannot be identified. The analysis only indicatesTable 1 Upstream regulators associated with the level of
anti-CMV IgG titre
Upstream
regulator
Predicted
activation state
Activation
z-score
Target molecules
in dataset
CD24 Activated 2.449 ADD3,EDEM3,MBNL1,
SMC4,SPG11,SYNE2
Mek Activated 2.446 ABCE1,DUSP6,LYAR,
MOB4,NOP58,OSBPL8
IFNL1 Activated 2.000 GBP1,SAMD9,
STAT1,TDRD7
AR Activated 2.000 ACTR3,CAST,CTSO,
STAT1,WIPF1
Upstream regulators in nonagenarians that are predicted to be associated with
the anti-CMV IgG titre are listed. An activation z-score >2 or < −2 is considered
significant. Target molecules are the molecules in our data set on whose
expression the prediction about the upstream regulator is based.the affected pathways based on the transcripts that correl-
ate with the anti-CMV titre. Therefore, the activation or
inhibition status of a given pathway cannot be directly
evaluated.
To gain information about the direction of changes that
are associated with an increased anti-CMV response, we
used the upstream regulator analysis tool. This analysis
can identify the molecules that may be responsible for the
gene expression changes that were observed in the data.
In our analysis, all identified upstream regulators were
predicted to be activated.
CD24 has not previously been associated with CMV
infection. However, polymorphisms in this gene are known
to affect the outcome of hepatitis B infection [17] and
possibly other viral infections. Interestingly, homology
exists between CD24 and the CMV UL139 ORF [18].
Mek is a complex that consists of MAP2K1-7. This
group of proteins has not been directly linked to CMV.
However, they are a part of the mitogen-activated phos-
phorylation cascade that mediates a wide range of cellular
signals that regulate processes such as cell growth, differ-
entiation, survival and immune responses [19].
The activation of the androgen receptor (AR) in nona-
genarians is unexpected. To our knowledge, the effect of
androgens on CMV infection has been studied only in
prostate cancer cells [20]. These investigators showed
that androgen activates the CMV major immediate early
(MIE) promoter via a protein kinase A-mediated path-
way. Thus, the androgen-dependent mechanism that is
involved in the up-regulation of the anti-CMV immune
response remains unknown. However, it is possible that
the association between CMV responses and androgens
is indirect; for example, androgens may enhance CMV-
induced cell damage, thereby increasing the release of
immunogenic viral antigens. Our recent finding dem-
onstrating that the association between high anti-CMV
titres and cardiovascular changes is restricted to males
[11] may support this explanation.
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similar antiviral properties as group I interferons. How-
ever, the magnitudes of gene expression changes and anti-
proliferative effects between type I and type III interferons
are different [21,22]. Nearly all cell types express IFNLs
after viral infection, and it can be assumed that most
viruses can induce their expression [21]. In mice, IFNL1
has been shown to decrease the number of hCMV
immediate-early 1 protein-positive cells in vitro [23].
The predicted activation of IFNL1 was the only viral
defence-associated feature that was linked with the
strength of the anti-CMV titre in our study. Because the
immune systems of elderly individuals are compromised,
this defence mechanism may offer an alternative solution
in an attempt to control the CMV infection.
However, the lack of a strong association with viral
defence may help to explain the adverse effects that are
associated with high anti-CMV IgG titre. Upon possible
CMV reactivation, the compromised immune system of
an elderly person is unable to produce the necessary
anti-viral reaction, thus leading to adverse outcomes
for the individual.
In our analysis, the anti-CMV IgG titre was associated
with few viral defence processes, and the majority of
associations were with the basic cellular processes. Our
results imply that the detrimental effects of high anti-
CMV IgG titre are mediated by changes in basic cellular
processes. Unfortunately, the direction of change in the
cellular processes that are associated with the anti-CMV
IgG titre cannot be deduced from our data. However, in
many analyses where the association of high anti-CMV
IgG titre and mortality or frailty have been studied,
other confounding factors have been taken into account
[7-10,12]. Thus, it can be speculated that the effect of high
anti-CMV titre is not merely a bystander effect, i.e., the
condition of the individual deteriorates for one reason or
another, thus leading to increased frailty and mortality and
elevated anti-CMV IgG titre, but that it can, in some cases,
also have a causative effect on the adverse outcomes.
In the young controls, we could not identify any tran-
scripts whose expressions were associated with the level of
the anti-CMV IgG titre. This finding may be due to inad-
equate statistical power because we only had 19 CMV
seropositive young controls. However, the result may also
reflect a true biological situation, i.e., the effects of CMV
are less pronounced in young controls. It is also possible
that the immune systems of young individuals have been
in contact with the virus for a shorter period of time com-
pared with those of nonagenarians, and thus, the associa-
tions may not be identifiable by our methods.
Conclusions
This study identified the molecular mechanisms that are
associated with the strength of the anti-CMV response.The majority of the affected processes were those of
basic cellular functions, and no notable associations
with immune system pathways were observed. The re-
ported associations between high anti-CMV IgG titre
and mortality and frailty are most likely mediated by
these basic cellular processes.
Materials and methods
Study population
The study population consisted of 144 nonagenarians,
138 of which were CMV seropositive (CMV+), and 30
young controls (19-30 years of age, median 23 years), of
which 19 were CMV seropositive. All of the study subjects
were of Western European descent. The nonagenarians
were a part of the on-going Vitality 90+ study, a prospect-
ive study involving home-dwelling and institutionalised
individuals who were 90 years of age and lived in the
city of Tampere. The nonagenarians who took part in this
study were recruited as described previously [24]. The
study protocol was approved by the ethics committee
of the city of Tampere. The young controls were healthy,
non-smoking laboratory personnel who lacked any medic-
ally diagnosed chronic diseases or infectious conditions
two weeks prior to blood sample drawing.
Sample collection
The blood samples were collected between 8 and 12 am
by a home-visiting, trained medical student. The samples
were collected into EDTA-containing tubes and were
directly subjected to PBMC separation using Ficoll-Paque
density gradients (Ficoll-Paque™ Premium, cat. no. 17-5442-
03, GE Healthcare Bio-Sciences AB, Uppsala, Sweden). The
PBMC layer was collected, and the cells were suspended
in 150 μl of RNAlater solution (Ambion Inc., Austin, TX,
USA) for use in microarray analyses. The plasma layer was
collected and stored at −70°C.
CMV serology
The anti-CMV IgG titre was measured using a commer-
cial enzyme-linked immunosorbent assay kit (Enzygnost®
Anti-CMV/IgG, Siemens Healthcare Diagnostics Products
GmbH, Marburg, Germany) to test the stored (−70°C)
plasma. The analysis was performed in the laboratory of
Tampere University Central Hospital, which is accredited
according to international standards (EN ISO/IEC 17025).
Seropositivity for CMV was defined according to the
manufacturer’s instructions as a plasma anti-CMV IgG
titre ≥ 230.
Physical performance
Maximal isometric handgrip strength and the Barthel
index were measured as described previously [25]. Briefly,
handgrip strength was measured using a hand-held dyna-
mometer. Each participant conducted three maximal trials
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used hand was accepted as the result. The 10-item Barthel
index measures the individual’s ability to perform the ac-
tivities that are required for daily living, such as mobility,
transfer, feeding and maintaining personal hygiene. Each
of the ten tasks is scored from 0-10, resulting in a total
score of 0-100, where 0 reflects total dependence and 100
reflects total independence.
RNA extraction and microarray analysis
RNA was purified using a miRNAeasy mini kit (Qiagen,
Hilden, Germany) according to the manufacturer’s proto-
col with on-column DNase digestion (AppliChem GmbH,
Darmstadt, Germany). The RNA concentration was deter-
mined based on the A260/A280 absorption ratio (Nano-
Drop® ND-1000; NanoDrop Technologies, Wilmington,
DE, USA) and using the Agilent RNA 6000 Nano Kit with
an Agilent 2100 Bioanalyser (Agilent Technologies, Santa
Clara, CA, USA).
RNA (330 ng) was used to prepare labelled cRNA
using the Illumina TotalPrep RNA Amplification Kit
(Ambion Inc., TX, USA) with overnight incubation
according to the manufacturer’s protocol. The quality
of the labelled cRNA was controlled using a 2100
Bioanalyser (Agilent).
Labelled cRNA (1 500 ng) was hybridised on a Hu-
manHT-12 v4 Expression BeadChip (Cat no. BD-103-0204,
Illumina Inc., CA, USA) according to Illumina’s protocol,
and the chips were scanned using Beadscan (Illumina Inc.).
The microarray analysis was performed at the Core Facility
of the Department of Biotechnology, University of Tartu.
The microarray data are available in the GEO database
(http://www.ncbi.nlm.nih.gov/geo/) under accession num-
ber GSE40366.
Data processing and statistical analysis
The preprocessing, filtering and microarray data analyses
were performed using the Chipster v2.6 program [26] (IT
Center for Science Ltd (CSC), Espoo, Finland). The lumi
pipeline was used for data preprocessing and normalisa-
tion. Array_Address_ID was used as a probe identifier,
background correction was performed using the bgAdjust.
affy package, and the data were log2-transformed and
normalised using the rsn method. The quality of the
expression data was verified using a box plot, density
plot and principal component analyses (PCA).
To filter out the non-expressed probes and poor quality
data, we included only probes with log2-transformed
expression values between 5 and 100 on all chips. After
applying this cut-off, 10 703 and 8 745 probes remained
for statistical testing in the young controls and nonage-
narians, respectively. To identify the transcripts with
expression levels that correlated with the anti-CMV
titre, the anti-CMV titre was log2-transformed andcorrelated with the expression values using Pearson’s
rho and Chipster’s correlate with the phenodata tool. We
considered probes with FDR < 0.20 as significant (corre-
sponding to Pearson’s rho above 0.2036 in nonagenarians).Pathway and upstream regulator analysis
To identify canonical pathways and upstream regulators
that were associated with anti-CMV IgG titres, we analysed
the acquired gene sets using the IPA software (Ingenuity®
Systems, www.ingenuity.com). According to the manu-
facturer, the canonical pathways are well-characterised
metabolic and cell signalling pathways that have been
curated and hand-drawn by PhD-level scientists. There
are 642 canonical pathways in the Ingenuity Knowledge
Base. The information used to construct the canonical
pathways was derived from journal articles, review articles,
textbooks and the KEGG Ligand database. The canonical
pathways are directional, and the affected pathways were
grouped into categories that were defined by Ingenuity®.
According to the manufacturer, the upstream regulators
in the IPA analysis are molecules that can affect the expres-
sion of other molecules. The Upstream Regulator Analysis
is based on the expected causal effects between upstream
regulators and targets, and the expected causal effects are
derived from the literature compiled in the Ingenuity®
Knowledge Base. The expression value of the upstream
regulator itself is not taken into account in the analysis.
All of the data sources provided by the Ingenuity Know-
ledge Base were included in the IPA analysis. For the asso-
ciation of molecules, only experimentally observed results
were accepted, and only human data were considered.
The HumanHT-12 v 4.0 was used as a reference set to
generate p-values for the pathways, and Fisher’s exact test
was used to calculate p-values for the pathways. For up-
stream regulator analysis, direct and indirect relationships
were included.
Using these parameters, 630 analysis ready molecules
were found. We considered a canonical pathway to be
significantly affected at p < 0.05 and when the pathway
contained a minimum of 3 genes. Pathways associated
with cancer and other diseases, as defined by Ingenuity
Systems®, were excluded from the analysis. Because our
dataset was not biased (all bias scores were below 0.25),
we used a z-score >2 or < −2 as a threshold for a significant
upstream regulator. The IPA analysis was performed on
the 18th of November 2013.Additional files
Additional file 1: Table S1. Transcripts correlated with anti-CMV IgG
titres in nonagenarians. List of all transcripts whose expression correlates
with the level of anti-CMV IgG titres in nonagenarians (Pearson’s correlation
coefficient > 0.2036, FDR < 0.20).
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the level of anti-CMV IgG titre in nonagenarians. P-value from Fisher’s
exact t-test.
Additional file 3: Table S3. Anti-CMV IgG titers in nonagenarians and
young controls.
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